ISDA

Entry Detail

PDB ID:

5KOS

Keywords:

HYDROLASE/HYDROLASE inhibitor

Title:

Discovery of TAK-272: A Novel, Potent and Orally Active Renin In-hibitor

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Homo sapiens

PDB Version:

Deposition Date:

2016-07-01

Release Date:

2016-11-16

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.41 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 21 3

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Renin
Chain IDs:A, B
Chain Length:337
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P00797 Pfam ID:PF00026 EC:3.4.23.15

Ligand Molecules

6VS

DMS

NAG

PEG

Primary Citation

Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.

Imaeda, Y, Tokuhara, H, Fukase, Y, Kanagawa, R, Kajimoto, Y, Kusumoto, K, Kondo, M, Snell, G, Behnke, C.A, Kuroita, T.Show

Acs Med.Chem.Lett. 7 933 938 (2016)

PMID: 27774132 DOI: 10.1021/acsmedchemlett.6b00251

Abstact

The aspartic proteinase renin is an attractive target for the treatment of hypertension and cardiovascular/renal disease such as chronic kidney disease and heart failure. We introduced an S1' site binder into the lead compound 1 guided by structure-based drug design (SBDD), and further optimization of physicochemical properties led to the discovery of benzimidazole derivative 10 (1-(4-methoxybutyl)-N-(2-methylpropyl)-N-[(3S,5R)-5-(morpholin-4-yl)carbonylpiperidin-3-yl]-1H-benzimidazole-2-carboxamide hydrochloride, TAK-272) as a highly potent and orally active renin inhibitor. Compound 10 demonstrated good oral bioavailability (BA) and long-lasting efficacy in rats. Compound 10 is currently in clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures